Clik here to view.
Roche’s CEO States that ‘Me-too’ Pharmaceutical Firms will ‘Disappear’
Drug makers who do not offer any genuine value will “disappear” over the next decade, according to Roche’s chief executive, Severin Schwan. Speaking at the Financial Times’ Pharmaceutical and...
View ArticleClik here to view.
Clinical Professionals Launch Graduate Training Academy
The Clinical Professionals Group is renowned for its innovation and added value services to the Life Sciences industry and is delighted to announce the launch of its unique Life Sciences Graduate...
View ArticleClik here to view.
Roche to Invest 3 Billion Swiss Francs on Basel Site
Roche has today announced new plans to spend 3 billion Swiss francs on upgrading and constructing new labs in Basel, Switzerland. Roche have put the plans forward to invest in creating modern,...
View ArticleClik here to view.
European Commission Partners with Pharma for €280m Ebola Initiative
The European Commission yesterday announced a new initiative with the European pharmaceutical industry for proposals under the Innovative Medicines Initiative to boost European research into Ebola. The...
View ArticleClik here to view.
Bayer Starts Phase II Clinical Trial of Riociguat
Bayer HealthCare has confirmed that they have begun a Phase II clinical trial of riociguat for the treatment of diffuse cutaneous systemic sclerosis (dcSSc). Systemic sclerosis is a rare multisystem,...
View ArticleClik here to view.
Positive Early-Stage Clinical Data for Biogen Alzheimer’s Drug
Biogen Idec has announced plans to move their investigational Alzheimer’s drug into Phase III trials, after receiving promising early-stage clinical data. Douglas Williams, Biogen Idec’s R&D chief,...
View ArticleClik here to view.
Johnson & Johnson and Vectura to Collaborate on Asthma / COPD Agreement
Johnson & Johnson and Vectura have announced a new partnership to develop anti-inflammatory therapies for asthma and chronic obstructive pulmonary disease (COPD). Vectura, who are respiratory...
View ArticleClik here to view.
Sosei Acquires Heptares Therapeutics for $180 Million
Japan’s Sosei have announced today that they have acquired Heptares Therapeutics, a UK based biotechnology company, in a deal that could be worth up to $400 million. Heptares Therapeutics specialises...
View ArticleClik here to view.
Postive Phase III Psoriasis Clinical Trial Results for Pfizer’s Xeljanz
Pfizer have announced positive Phase III clinical trial results for their JAK inhibitor, Xeljanz (tofacitinib). The results from data taken from two Phase III clinical trials provide additional support...
View ArticleClik here to view.
Initiatives Could Create 30,000 – 60,000 New UK Jobs, Claim BIA
The BioIndustry Association (BIA) has published a number of initiatives that they claim would rank the UK among the three largest biotech clusters in the world, and could create between 30,000 and...
View ArticleClik here to view.
The Importance of Clinical Trials
International Clinical Trials day takes place on the 20th May each year to honour the day James Lind began the first clinical trials with control groups. The trial involved 12 people who were given...
View Article
